189 related articles for article (PubMed ID: 23819905)
1. Interrogating differences in expression of targeted gene sets to predict breast cancer outcome.
Andres SA; Brock GN; Wittliff JL
BMC Cancer; 2013 Jul; 13():326. PubMed ID: 23819905
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of genes with estrogen receptor-α and progesterone receptor in human breast carcinoma tissue.
Andres SA; Wittliff JL
Horm Mol Biol Clin Investig; 2012 Dec; 12(1):377-90. PubMed ID: 25436697
[TBL] [Abstract][Full Text] [Related]
3. A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer.
Biermann J; Nemes S; Parris TZ; Engqvist H; Rönnerman EW; Forssell-Aronsson E; Steineck G; Karlsson P; Helou K
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1619-1628. PubMed ID: 28877888
[No Abstract] [Full Text] [Related]
4. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
[TBL] [Abstract][Full Text] [Related]
5. Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer.
Karlsson E; Delle U; Danielsson A; Olsson B; Abel F; Karlsson P; Helou K
BMC Cancer; 2008 Sep; 8():254. PubMed ID: 18778486
[TBL] [Abstract][Full Text] [Related]
6. Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.
Bendrat K; Fritz P; Müller S; Brockmöller S; Debus A; Friedrichs K; Lindner C; Brinkmann F; Heidemann E; Niendorf A
Anticancer Res; 2016 Aug; 36(8):3855-63. PubMed ID: 27466487
[TBL] [Abstract][Full Text] [Related]
7. Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients.
Tong D; Heinze G; Pils D; Wolf A; Singer CF; Concin N; Hofstetter G; Schiebel I; Rudas M; Zeillinger R
BMC Cancer; 2010 Dec; 10():682. PubMed ID: 21159173
[TBL] [Abstract][Full Text] [Related]
8. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
[TBL] [Abstract][Full Text] [Related]
9. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
10. Copy number profiling of Oncotype DX genes reveals association with survival of breast cancer patients.
Ahmed W; Malik MFA; Saeed M; Haq F
Mol Biol Rep; 2018 Dec; 45(6):2185-2192. PubMed ID: 30225582
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
12. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
13. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients.
Tjensvoll K; Oltedal S; Farmen RK; Shammas FV; Heikkilä R; Kvaløy JT; Gilje B; Smaaland R; Nordgård O
Clin Breast Cancer; 2010 Oct; 10(5):378-84. PubMed ID: 20920982
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide screen identifies a novel prognostic signature for breast cancer survival.
Mao XY; Lee MJ; Zhu J; Zhu C; Law SM; Snijders AM
Oncotarget; 2017 Feb; 8(8):14003-14016. PubMed ID: 28122328
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients.
Zhao Y; Wang Y; Zhu F; Zhang J; Ma X; Zhang D
Clin Exp Med; 2020 May; 20(2):249-259. PubMed ID: 31980982
[TBL] [Abstract][Full Text] [Related]
16. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Esserman LJ; Moore DH; Tsing PJ; Chu PW; Yau C; Ozanne E; Chung RE; Tandon VJ; Park JW; Baehner FL; Kreps S; Tutt AN; Gillett CE; Benz CC
Breast Cancer Res Treat; 2011 Sep; 129(2):607-16. PubMed ID: 21597921
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells.
Daniels MW; Brock GN; Wittliff JL
Breast Cancer Res Treat; 2017 Jan; 161(2):245-258. PubMed ID: 27858316
[TBL] [Abstract][Full Text] [Related]
18. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
Buechler SA; Gökmen-Polar Y; Badve SS
Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
